Evidence map›Paper›PMID 41394271›Full record

ArticleMolecular therapy. Oncology2025

An oncolytic herpes simplex virus armed with IL-12 for treatment of preclinical glioblastoma.

Joseph W Jackson, Bonnie L Hall, Chaim Sneiderman, Amy Webb, Trevor J Hancock, Marina Vlasyuk, Lisa Bailey, Molly Xiaokui, Isaac H Solomon, Keith Ligon and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Joseph W JacksonDepartment of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN 37920, USA.
Bonnie L HallDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA.
Chaim SneidermanDepartment of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA.
Amy WebbDepartment of Biostatistics, The Ohio State University, Columbus, OH 43210, USA.
Trevor J HancockDepartment of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN 37920, USA.
Marina VlasyukDepartment of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN 37920, USA.
Lisa BaileyDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA.
Molly XiaokuiDepartment of Biostatistics, The Ohio State University, Columbus, OH 43210, USA.
Isaac H SolomonDivision of Neuropathology, Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Keith LigonDivision of Neuropathology, Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
William F GoinsDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA.
Gary KohanbashDepartment of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA.
E Antonio ChioccaHarvey W. Cushing Neuro-oncology Laboratories (HCNL), Department of Neurosurgery, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.
Joseph C GloriosoDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is a devastating brain cancer with a 5-year survival rate of ∼5% despite current treatment regimens. Multiple oncolytic herpes simplex viruses (oHSV) have been designed for GBM therapy, but clinical trials have thus far met with limited success. A potential reason for this lack of efficacy is the immunosuppressive tumor microenvironment (TME) of GBM. Here we used an oHSV (KOS strain) armed with interleukin (IL)-12 (oHSV:IL-12) in an attempt to overcome this immunosuppression and analyzed the immunological and therapeutic impact in murine CT2A and GL261N4 orthotopic syngeneic glioma models. Unarmed oHSV failed to enhance survival in animals bearing syngeneic GBM tumors. However, oHSV:IL-12 induced significant and durable therapeutic benefits. TME interrogation following oHSV:IL-12 therapy revealed a significant accumulation of macrophages and cytotoxic T cells. Further investigation using single cell RNA-sequencing of GL261N4 tumors treated with either oHSV or oHSV:IL-12, indicated that oHSV:IL-12 induced robust macrophage accumulation within the TME and encouraged T cell receptor clonotype expansion compared to controls. These data point to the propensity of the IL-12 transgene to manipulate the myeloid compartment within the glioma TME, promote T cell expansion, and improve survival.

Indexed as

cancerGBMHSVimmunotherapyoncolytic

Identifiers

PMID41394271
PMCPMC12696497

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.